Month: May 2016

May 18, 2016
EMA discounts increased inhibitor risk with Kogenate and Helixate

13 May 2016 Currently available evidence does not confirm that Kogenate Bayer/Helixate NexGen is associated with an increased risk of factor VIII inhibitors, compared with other recombinant factor VIII products in previously untreated patients, accordion to Europe’s drugs regulator. The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency has concluded a review of …

Read article